HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reich-Zeliger, S. Articles by Reisner, Y. Search for Related Content PubMed PubMed Citation Articles by Reich-Zeliger, S. Articles by Reisner, Y.

Tolerance Induction by Veto CTLs in the TCR Transgenic 2C Mouse Model. II. Deletion of Effector Cells by Fas-Fas Ligand Apoptosis¹

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel

The direct assay of veto CTLs in the 2C mouse model enables monitoring, by FACS, the fate of the TCR transgenic effector CD8⁺ T cells, the transgene of which can be stained with clonotypic Ab 1B2. After the addition of veto cells, CD8⁺1B2⁺ effector cells increasingly express annexin V, and maximal apoptosis is attained 72 h after initiation of MLR. This veto activity can be partially blocked by anti-CD8 Abs directed against the allele expressed by the veto CTLs, but not by the effector cells. When effector CD8⁺ T cells were from 2C mice, which lack Fas expression ((2CX lpr)F₂), deletion of effector cells was not exhibited by veto cells. The protein levels of the apoptosis inhibitors FLIP and Bcl2 in purified CD8⁺1B2⁺ effector cells at different time points after MLR showed an initial up-regulation of these inhibitors, with marked reduction of FLIP, but not of Bcl2, by 48 h after initiation of culture. Taken together, these results are in accordance with a Fas-FasL-based mechanism in which prolonged binding between the effector cell and the veto cell might be required to allow FLIP to be down-regulated. Such prolonged interaction might be afforded through the interaction of CD8 molecules on the veto cell with the 3 domain of H2 class 1 on the effector cell.

This article has been cited by other articles:

				G. Strauss, J. A. Lindquist, N. Arhel, E. Felder, S. Karl, T. L. Haas, S. Fulda, H. Walczak, F. Kirchhoff, and K.-M. Debatin CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling J. Exp. Med., June 8, 2009; 206(6): 1379 - 1393. [Abstract] [Full Text] [PDF]

				J. Mariotti, J. Foley, K. Ryan, N. Buxhoeveden, V. Kapoor, S. Amarnath, and D. H. Fowler Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway Blood, December 1, 2008; 112(12): 4765 - 4775. [Abstract] [Full Text] [PDF]

				J. Mariotti, J. Foley, U. Jung, T. Borenstein, N. Kantardzic, S. Han, J. T. Hanson, E. Wong, N. Buxhoeveden, J. B. Trepel, et al. Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection J. Immunol., January 1, 2008; 180(1): 89 - 105. [Abstract] [Full Text] [PDF]

				S. Reich-Zeliger, E. Bachar-Lustig, A. Bar-Ilan, and Y. Reisner Tolerance Induction in Presensitized Bone Marrow Recipients by Veto CTLs: Effective Deletion of Host Anti-Donor Memory Effector Cells J. Immunol., November 15, 2007; 179(10): 6389 - 6394. [Abstract] [Full Text] [PDF]

				M. Pearl-Yafe, E. S. Yolcu, J. Stein, O. Kaplan, I. Yaniv, H. Shirwan, and N. Askenasy Fas Ligand Enhances Hematopoietic Cell Engraftment Through Abrogation of Alloimmune Responses and Nonimmunogenic Interactions Stem Cells, June 1, 2007; 25(6): 1448 - 1455. [Abstract] [Full Text] [PDF]